EmbryoDx Solutions
Improving IVF Success with Our Advanced Embryo Selection Technology
Choosing the Healthiest Embryo
Scientific Innovation
EmbryoDx is developing a technology capable of vastly improving success rates of In Vitro Fertilization (IVF) by assisting in the selection of embryo implant candidates.
Micro-Environment Analysis
EmbryoDx provides non-invasive biomarker readouts from the micro-environment of the cultured embryo, providing doctors with clear information to make more informed treatment decisions.
Optimizing Outcomes
Our technology aids in selecting the most viable embryo for IVF, reducing complications, and increasing the probability of successful pregnancies.
Every Year:
Challenges in Preimplantation Embryo Selection
Selection of the healthiest embryo to transfer is arguably the most studied problem in both human and veterinarian reproductive medicine. During IVF, the process of embryo selection can be challenging due to the subjectivity of the morphological criteria used by embryologists.
​
Current invasive and non-invasive methods of embryo selection include:
-
Morphologic assessment of embryos - selection based on number of cells, presence of cellular fragments, or symmetry of blastomeres.
-
Time lapse technology - observation of how quickly the embryo develops in vitro.
-
Preimplantation embryo testing (PGT) - an invasive procedure where 3-7 cells are removed at the blastocyst stage and undergo chromosomal analysis.
​​
Even with any of these methods, and transferring multiple embryos, the probability of successful pregnancy is not guaranteed.
Despite advances made in IVF technology, more than 85% of embryos are inviable, necessitating multiple transfers to conceive. At times, multiple embryos need to be transferred. This increases the number of multiple births, which can significantly compromise maternal and newborn health, such that the costs of care of these pregnancies greatly exceeds the treatment itself. Furthermore, embryos generated external to the body are exposed to non-physiologic conditions that can profoundly affect their development and impair adult health.
Newborns conceived through IVF can experience premature birth, with associated neurological, intestinal, respiratory, and visual impairments.
More than 7 million American women have used fertility services, with assisted reproduction doubling in the last decade. In 2018, these procedures yielded 2.2% of all U.S. births.
Thus, there is a great need to develop technologies that can identify healthy embryos for transfer, to maximize implantation, minimize need for multiple embryo transfers, and produce healthier offspring. Addressing these challenges head-on, EmbryoDx’s groundbreaking technology offers a beacon of hope.
The Solution
EmbryoDx is revolutionizing IVF outcomes with a novel method of pre-implantation embryo selection. The technology under development is capable of improving the success rate of IVF by measuring metabolites secreted from cultured embryos, providing a clear indication of which embryo has the highest chance to implant. This will not only increase the likelihood of pregnancy but also minimize the need for multiple embryo implantations, reducing potential complications.​
The EmbryoDx system will feature a compact reader device specifically designed to help doctors pinpoint embryos that have the highest probability of leading to a singular, healthy pregnancy. This system is complemented by a one-time-use test which evaluates the cultured media through our proprietary, non-invasive method, Our aim is to be at the cutting edge of creating and bringing to market a tool that meets the specific needs of IVF clinics, especially embryologists, assisting in selecting the most suitable embryos for implantation.​
The ripple effect of this innovation is vast, benefiting not just the patients but also IVF clinics, payors, and society at large. The future of IVF, with EmbryoDx's technology at the helm, looks brighter and more promising than ever.